Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272558
Status:
COMPLETED
Last Update Posted:
2009-09-18
First Post:
2006-01-03
Brief Title:
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
Sponsor:
Rigshospitalet Denmark
Organization:
Rigshospitalet Denmark
Study Overview
Official Title:
Phase II Study of Carboplatin and Vinorelbine iv Day 1 and Orally Day 8 for Malignant Pleural Mesothelioma
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma
Detailed Description:
Chemotherapy with carboplatin iv day one in each cycle Vinorelbine iv day one and orally day 8 in each cycle repeat new cycle every 3 weeks Total of 6 cycles
Endpoint is response rate secondary endpoints survival and toxicity
Endpoint is response rate secondary endpoints survival and toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None